An 18-month-old, previously well boy presents to his primary care pediatrician with a 2-day history of fever, fussiness, and what his mother interprets as a sore throat because he is crying, eating ...

For centuries, bullous pemphigoid (BP) was grouped with and considered a condition similar to pemphigus vulgaris (PV). In 1953, however, Lever recognized BP as a disorder distinct from PV. 9 BP, the ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Clinical measurements of skin-related quality of life (SRQL) may aid in detecting critical disease severity information. Skin-related quality of life (SRQL) may be associated with flare-ups in ...

Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...

Autoimmune bullous diseases comprise a group of conditions characterised by the formation of blisters on the skin and mucous membranes due to aberrant immune responses. Central to many of these ...

(RTTNews) - Drug makers Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Wednesday that ADEPT study of Dupixent (dupilumab) in bullous pemphigoid or BP met the primary and all key ...

An autoimmune blistering disease of the mucous membranes and skin, pemphigus vulgaris (PV) derives its name from the Greek word, pemphix, for blister. 1 PV is characteristically seen in older patients ...